The evolution of our understanding of the biology and management of the
disease once called Hodgkin disease, now called Hodgkin
lymphoma (HL), has closely paralleled the growth of
the American Society of Clinical Oncology (ASCO) since 1964. It was the
first advanced malignancy of a major organ system in
adults to be cured by chemotherapy,1
and this proof of principle of the curability of cancer by drugs served
as a stimulus for the use of chemotherapy in other
tumors as an adjunct to surgery or radiation. The
principles developed to diagnose, stage, and treat HL crossed the
specialties
of medical and pediatric oncology, therapeutic
radiology, diagnostic radiology, surgery, and pathology, placing HL as a
model
for cross-specialty collaboration in other tumors.
This collaborative model led to a decrease in the US national mortality
as a result of HL by 75%, even before 1980.2
Journal of Clinical Oncology
Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, DeVita DT.
doi: 10.1200/JCO.2013.53.1194 JCO January 20, 2014 vol. 32 no. 3 163-168
No comments:
Post a Comment